BR112022017770A2 - Polinucleotídeo isolado; painel de polinucleotídeos isolados; kit que compreende o polinucleotídeo isolado ou painel; microarranjo; reagente; kit que compreende o reagente; kit que compreende o polinucleotídeo isolado ou painel; método de diagnóstico complementar; método para classificar um indivíduo para elegibilidade para um tratamento; método para rastrear um indivíduo ou uma população de indivíduos para um tratamento; método para monitorar um indivíduo durante um tratamento; método para identificar um alvo de fármaco; método para o tratamento de doença ou transtorno do sistema nervoso central (snc) em um indivíduo; uso - Google Patents
Polinucleotídeo isolado; painel de polinucleotídeos isolados; kit que compreende o polinucleotídeo isolado ou painel; microarranjo; reagente; kit que compreende o reagente; kit que compreende o polinucleotídeo isolado ou painel; método de diagnóstico complementar; método para classificar um indivíduo para elegibilidade para um tratamento; método para rastrear um indivíduo ou uma população de indivíduos para um tratamento; método para monitorar um indivíduo durante um tratamento; método para identificar um alvo de fármaco; método para o tratamento de doença ou transtorno do sistema nervoso central (snc) em um indivíduo; usoInfo
- Publication number
- BR112022017770A2 BR112022017770A2 BR112022017770A BR112022017770A BR112022017770A2 BR 112022017770 A2 BR112022017770 A2 BR 112022017770A2 BR 112022017770 A BR112022017770 A BR 112022017770A BR 112022017770 A BR112022017770 A BR 112022017770A BR 112022017770 A2 BR112022017770 A2 BR 112022017770A2
- Authority
- BR
- Brazil
- Prior art keywords
- individual
- treatment
- kit
- panel
- isolated polynucleotide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062986603P | 2020-03-06 | 2020-03-06 | |
| PCT/US2021/019265 WO2021178166A1 (en) | 2020-03-06 | 2021-02-23 | Compositions and methods for assessing the efficacy of inhibitors of neurotransmitter transporters |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022017770A2 true BR112022017770A2 (pt) | 2022-11-29 |
Family
ID=77613738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022017770A BR112022017770A2 (pt) | 2020-03-06 | 2021-02-23 | Polinucleotídeo isolado; painel de polinucleotídeos isolados; kit que compreende o polinucleotídeo isolado ou painel; microarranjo; reagente; kit que compreende o reagente; kit que compreende o polinucleotídeo isolado ou painel; método de diagnóstico complementar; método para classificar um indivíduo para elegibilidade para um tratamento; método para rastrear um indivíduo ou uma população de indivíduos para um tratamento; método para monitorar um indivíduo durante um tratamento; método para identificar um alvo de fármaco; método para o tratamento de doença ou transtorno do sistema nervoso central (snc) em um indivíduo; uso |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12612661B2 (https=) |
| EP (1) | EP4106872A4 (https=) |
| JP (1) | JP2023515665A (https=) |
| KR (1) | KR20230005816A (https=) |
| CN (1) | CN115515680A (https=) |
| AR (1) | AR121515A1 (https=) |
| AU (1) | AU2021231683A1 (https=) |
| BR (1) | BR112022017770A2 (https=) |
| CA (1) | CA3174572A1 (https=) |
| IL (1) | IL296168A (https=) |
| MX (1) | MX2022010816A (https=) |
| TW (1) | TW202146660A (https=) |
| WO (1) | WO2021178166A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT202000019303A1 (it) * | 2020-08-05 | 2022-02-05 | Univ Degli Studi Di Brescia | Analoghi strutturali del metilfenidato come agenti disease-modifying della malattia di parkinson |
| CN114848835B (zh) * | 2022-03-22 | 2023-08-25 | 暨南大学 | 塞来昔布的聚乙二醇修饰及连接叶酸基团的靶向药物分子及制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6945457B1 (en) * | 1996-05-10 | 2005-09-20 | Transaction Holdings Ltd. L.L.C. | Automated transaction machine |
| JP4198582B2 (ja) * | 2003-12-02 | 2008-12-17 | 独立行政法人科学技術振興機構 | タンタルオキシナイトライド酸素還元電極触媒 |
| WO2007128884A1 (en) * | 2006-05-09 | 2007-11-15 | Oy Jurilab Ltd | Novel genes and markers in type 2 diabetes and obesity |
| US20080299125A1 (en) | 2006-06-05 | 2008-12-04 | Perlegen Sciences, Inc. | Genetic basis of treatment response in depression patients |
| WO2008065544A2 (en) | 2006-09-11 | 2008-06-05 | Mcgill University | Genetic predictors of risk for type 2 diabetes mellitus |
| EP2243834A1 (en) | 2007-03-05 | 2010-10-27 | Cancer Care Ontario | Assessment of risk for colorectal cancer |
| US20170029892A1 (en) | 2009-05-29 | 2017-02-02 | Jay L. Lombard | Methods and compositions for the treatment of post-traumatic stress disorder |
| US8355927B2 (en) * | 2010-11-05 | 2013-01-15 | Genomind, Llc | Neuropsychiatric test reports |
| EP2707498B1 (en) | 2011-01-31 | 2018-01-17 | Denovo Biomarkers Inc. | Method for discovering pharmacogenomic biomarkers |
| WO2012156515A1 (en) * | 2011-05-18 | 2012-11-22 | Rheinische Friedrich-Wilhelms-Universität Bonn | Molecular analysis of acute myeloid leukemia |
| CA2838207A1 (en) | 2011-06-08 | 2012-12-13 | Denovo Biopharma (Hangzhou) Ltd. Co. | Methods and compositions of predicting activity of retinoid x receptor modulator |
| US20140274764A1 (en) | 2013-03-15 | 2014-09-18 | Pathway Genomics Corporation | Method and system to predict response to treatments for mental disorders |
| US20170253928A1 (en) | 2013-03-15 | 2017-09-07 | Pathway Genomics Corporation | Method and system to predict response to treatments for mental disorders |
| TR201907106T4 (tr) | 2014-03-14 | 2019-06-21 | Caredx Inc | Bir transplant alıcısında immünosüpresif terapileri izleme yöntemleri. |
-
2021
- 2021-02-23 CA CA3174572A patent/CA3174572A1/en active Pending
- 2021-02-23 KR KR1020227034374A patent/KR20230005816A/ko active Pending
- 2021-02-23 EP EP21764344.4A patent/EP4106872A4/en active Pending
- 2021-02-23 BR BR112022017770A patent/BR112022017770A2/pt unknown
- 2021-02-23 AU AU2021231683A patent/AU2021231683A1/en active Pending
- 2021-02-23 JP JP2022552541A patent/JP2023515665A/ja active Pending
- 2021-02-23 WO PCT/US2021/019265 patent/WO2021178166A1/en not_active Ceased
- 2021-02-23 IL IL296168A patent/IL296168A/en unknown
- 2021-02-23 US US17/905,511 patent/US12612661B2/en active Active
- 2021-02-23 MX MX2022010816A patent/MX2022010816A/es unknown
- 2021-02-23 CN CN202180031602.1A patent/CN115515680A/zh active Pending
- 2021-03-05 AR ARP210100576A patent/AR121515A1/es unknown
- 2021-03-05 TW TW110107927A patent/TW202146660A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US12612661B2 (en) | 2026-04-28 |
| CN115515680A (zh) | 2022-12-23 |
| WO2021178166A1 (en) | 2021-09-10 |
| CA3174572A1 (en) | 2021-09-10 |
| US20230193388A1 (en) | 2023-06-22 |
| MX2022010816A (es) | 2022-12-13 |
| JP2023515665A (ja) | 2023-04-13 |
| TW202146660A (zh) | 2021-12-16 |
| EP4106872A4 (en) | 2024-04-10 |
| EP4106872A1 (en) | 2022-12-28 |
| KR20230005816A (ko) | 2023-01-10 |
| IL296168A (en) | 2022-11-01 |
| AU2021231683A1 (en) | 2022-09-22 |
| AR121515A1 (es) | 2022-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gkatza et al. | Cytosine-5 RNA methylation links protein synthesis to cell metabolism | |
| Maltby et al. | Genome-wide DNA methylation profiling of CD8+ T cells shows a distinct epigenetic signature to CD4+ T cells in multiple sclerosis patients | |
| Calligaris et al. | Blood transcriptomics of drug-naive sporadic Parkinson’s disease patients | |
| Al‐Mashhadi et al. | Oxidative glial cell damage associated with white matter lesions in the aging human brain | |
| Álvarez-Sánchez et al. | Peripheral CD39-expressing T regulatory cells are increased and associated with relapsing-remitting multiple sclerosis in relapsing patients | |
| Munkholm et al. | A composite peripheral blood gene expression measure as a potential diagnostic biomarker in bipolar disorder | |
| Berta et al. | Gene expression profiling of cutaneous injured and non-injured nociceptors in SNI animal model of neuropathic pain | |
| Gavin et al. | Growth arrest and DNA-damage-inducible, beta (GADD45b)-mediated DNA demethylation in major psychosis | |
| Fisher et al. | Methylomic analysis of monozygotic twins discordant for childhood psychotic symptoms | |
| BR112018071543A2 (pt) | execução do teste de suscetibilidade antimicrobiana e sistemas e métodos relacionados | |
| Nevalainen et al. | Transcriptomic and epigenetic analyses reveal a gender difference in aging-associated inflammation: the Vitality 90+ study | |
| Berge et al. | The multiple sclerosis susceptibility genes TAGAP and IL2RA are regulated by vitamin D in CD4+ T cells | |
| Radtke et al. | Expression of miRNA‐371a‐3p in seminal plasma and ejaculate is associated with sperm concentration | |
| BRPI0410283B8 (pt) | método de caracterização de um gene de região variável de receptor de células t ou imunoglobulina rearranjado | |
| Sabunciyan et al. | Association of DNA methylation with acute mania and inflammatory markers | |
| BR112022017770A2 (pt) | Polinucleotídeo isolado; painel de polinucleotídeos isolados; kit que compreende o polinucleotídeo isolado ou painel; microarranjo; reagente; kit que compreende o reagente; kit que compreende o polinucleotídeo isolado ou painel; método de diagnóstico complementar; método para classificar um indivíduo para elegibilidade para um tratamento; método para rastrear um indivíduo ou uma população de indivíduos para um tratamento; método para monitorar um indivíduo durante um tratamento; método para identificar um alvo de fármaco; método para o tratamento de doença ou transtorno do sistema nervoso central (snc) em um indivíduo; uso | |
| Fries et al. | Integrated transcriptome and methylome analysis in youth at high risk for bipolar disorder: a preliminary analysis | |
| Kuan et al. | Single‐cell transcriptomics analysis of mild cognitive impairment in World Trade Center disaster responders | |
| Zhao et al. | APOE deficiency impacts neural differentiation and cholesterol biosynthesis in human iPSC-derived cerebral organoids | |
| Ng et al. | Brain-derived neurotrophic factor as a biomarker in cancer-related cognitive impairment among adolescent and young adult cancer patients | |
| Harris et al. | Colonic mucosal epigenome and microbiome development in children and adolescents | |
| Di Persio et al. | Whole-genome methylation analysis of testicular germ cells from cryptozoospermic men points to recurrent and functionally relevant DNA methylation changes | |
| Manna et al. | A comprehensive examination of the role of epigenetic factors in multiple sclerosis | |
| Kebir et al. | Epigenetic variability in conversion to psychosis: novel findings from an innovative longitudinal methylomic analysis | |
| Bortoluzzi et al. | DNA methylation in adolescents with anxiety disorder: a longitudinal study |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |